We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Corgenix Diagnostic Ebola Test Research Earns Abstract Award

By LabMedica International staff writers
Posted on 01 Aug 2014
Print article
The Best Annual Meeting Abstract Award is given by the AACC Critical and Point-of-Care Testing Division in recognition of outstanding research for abstracts submitted and posters presented at the AACC annual meeting.

The Ebola research award and Lassa fever oral abstract of Corgenix Medical (Broomfield, CO, USA) receive the award recognized for its high quality poster abstract, “Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection,” presented at the AACC conference. Douglass Simpson, BS, MS, Corgenix president and CEO comments, “We’re pleased to accept this prestigious award, and we must also recognize our academic, research, and industry partners at the Viral Hemorrhagic Fever Consortium (VHFC), who have helped to make this possible. We are continuing with our efforts to develop breakthrough diagnostic products for detecting Ebola, Lassa, and other biologic agents. Rapid, accurate testing for these agents in difficult environments is critical to global public health and defense against bioterrorism threats.”

Corgenix and the VHFC were recently awarded a three-year, USD 2.9 million National Institutes of Health (NIH) grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV rapid diagnostic test for the Lassa fever virus.

The current Ebola outbreak in West Africa is the largest ever recorded. Mr. Simpson said that it is clear that point-of-care (POC) testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola, and Marburg.

Corgenix is also presenting an oral abstract titled “Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone.” The study was conducted to better identify and treat patients with Lassa, which can be difficult to distinguish from other illnesses such as malaria. Study results are being presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry.

Related Links:

Corgenix Medical
National Institutes of Health


Gold Supplier
INFLUENZA A/B RAPID TEST
COMBO INFLUENZA A+B-CHECK-1
New
Gold Supplier
Rapid PCR Diagnostic System
Accula System
New
Gold Supplier
Automated Immune Analyzer
UNION Immune Analyzer
New
Silver Supplier
Automated Body Fluid Cell Count Control
Cell-Chex Auto

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.